Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
NCT00880061 · National Institute of Neurological Disorders and Stroke (NINDS) · PHASE1 · terminated · last registry update 2018-07-05 · Glioma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Institute of Neurological Disorders and Stroke (NINDS) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL4R in glioma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision